NCT01529853 - To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

SAR156597

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Placebo (for SAR156597)

"Pharmaceutical form: solution~Route of administration: subcutaneous"

Trial Locations (21)

10021

Investigational Site Number 840013, New York

29406

Investigational Site Number 840010, Charleston

32209

Investigational Site Number 840009, Jacksonville

32216

Investigational Site Number 840011, Jacksonville

40766

Investigational Site Number 484003, Mexico City

55455

Investigational Site Number 840003, Minneapolis

60153

Investigational Site Number 840005, Maywood

60435

Investigational Site Number 840004, Joliet

60637

Investigational Site Number 840006, Chicago

64460

Investigational Site Number 484002, Monterrey

67208

Investigational Site Number 840002, Wichita

95817

Investigational Site Number 840008, Sacramento

7500710

Investigational Site Number 152001, Santiago

8380456

Investigational Site Number 152002, Santiago

45267-0542

Investigational Site Number 840014, Cincinnati

T6G 2B7

Investigational Site Number 124003, Edmonton

L8N 4A6

Investigational Site Number 124001, Hamilton

V5Z 1M9

Investigational Site Number 124002, Vancouver

750-0691

Investigational Site Number 152003, Santiago

08036

Investigational Site Number 724001, Barcelona

08907

Investigational Site Number 724002, Barcelona